New Chief Executive Takes Helm at Johnson & Johnson During Turbulent Time

NEW BRUNSWICK, NJ—The new chief executive of Johnson & Johnson, Alex Gorsky, announced at the company's shareholders meeting on April 26 that he would make their customers the first priority, according to a report on MyCentralJersey.com.

In a separate article, MyCentralJersey.com reported that seven different organizations protested the annual shareholders meeting, held at the at the Hyatt Regency Hotel on Albany Street.

Gorsky is taking over for former CEO William Weldon, who ran the company as it came under fire for various lawsuits over the drug Risperdal. Lawsuits challenging the way the drug was marketed were filed by several states and the federal government. Currently, the State of Arkansas won a $1.1B judment from the company last month.

And NewBrunswickToday.com reported that the company is looking at a $1.8B bill to settle the federal government's claims against Risperdal.

Handling the lawsuits will be one of the many challenges Gorsky has to face during tenure as CEO of the world's largest pharmaceutical corporation.

Editor at New Brunswick Today | (732) 993-9697 | editor@newbrunswicktoday.com | Website

Charlie is the founder and editor of New Brunswick Today, and the winner of the Awbrey Award for Community-Oriented Local Journalism. He is a proud Rutgers University journalism graduate and a community organizer, and was an independent candidate for Mayor of New Brunswick in 2018.